These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14503798)

  • 1. Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
    Esteban E; Modollel A; González de Sande L; Palacio I; Muñiz I; Fernández Y; Corral N; Fra J; Sala M; Vieitez JM; Estrada E; Lacave AJ;
    Breast Cancer Res Treat; 2003 Aug; 80(3):257-65. PubMed ID: 14503798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
    Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
    Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
    Ibrahim NK; Rahman Z; Valero V; Murray JL; Frye D; Hortobagyi GN
    Cancer Invest; 2002; 20(1):29-37. PubMed ID: 11852999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer.
    Vici P; Foggi P; Colucci G; Capomolla E; Brandi M; Giotta F; Gebbia N; Di Lauro L; Valerio MR; Paoletti G; Belli F; Pizza C; Giannarelli D; Lopez M
    Anticancer Res; 2005; 25(2B):1309-14. PubMed ID: 15865083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer.
    Nisticò C; Garufi C; Barni S; Frontini L; Gallà DA; Giannarelli D; Vaccaro A; D'Ottavio AM; Terzoli E
    Ann Oncol; 1999 Aug; 10(8):937-42. PubMed ID: 10509155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
    Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
    J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines.
    Martí JL; Bueso P; Mayordomo JI; Isla MD; Saenz A; Escudero P; Murillo L; Filipovich E; Andres R; Tres A
    Ann Oncol; 2001 Aug; 12(8):1061-5. PubMed ID: 11583186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
    Serin D; Verrill M; Jones A; Delozier T; Coleman R; Kreuser ED; Mross K; Longerey B; Brandely M
    Br J Cancer; 2005 Jun; 92(11):1989-96. PubMed ID: 15928659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.
    Mayordomo JI; Milla A; Morales S; Yubero A; Lorenzo A; Baena JM; Modolell A; Sanz J; Illarramendi J; Garcia MJ; Machengs I; Burrilo MA; Tres A
    Clin Breast Cancer; 2004 Jun; 5(2):131-5. PubMed ID: 15245617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.
    Gómez-Bernal A; Cruz JJ; García-Palomo A; Arizcun A; Pujol E; Diz P; Martín G; Fonseca E; Sánchez P; Rodríguez C; del Barco E; López Y
    Am J Clin Oncol; 2003 Apr; 26(2):127-31. PubMed ID: 12714881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.
    Shamseddine AI; Otrock ZK; Khalifeh MJ; Yassine HR; Charafeddine M; Abdel-Khalek Z; Chehal A; Bitar N; Jalloul R; Dheiny M; Dandashi A; Wehbeh M; El-Saghir NS
    Oncology; 2006; 70(5):330-8. PubMed ID: 17164589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study.
    Riccardi A; Brugnatelli S; Danova M; Giordano M; Pugliese P; Luchena G; Grasso D; Trotti G; Bertè R; Pansini G; Tinelli C
    Tumori; 2006; 92(1):6-12. PubMed ID: 16683377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.
    Fabi A; Papaldo P; Pino MS; Ferretti G; Carlini P; Pacetti U; Di Cosimo S; Nardoni C; Giannarelli D; Sacchi I; Cognetti F
    Anticancer Res; 2004; 24(3b):1963-7. PubMed ID: 15274385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
    Im SA; Kim SB; Lee MH; Im YH; Lee KH; Song HS; Lee MA; Lee J; Lee NS; Ham HS; Kim TY; Park YH; Lee KE; Kim KW; Seo JH; Lee SN; Hong YS; Bang YJ; Kim WK; Park HS
    Oncol Rep; 2005 Aug; 14(2):481-7. PubMed ID: 16012734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer.
    Campone M; Blasinska-Morawiec M; Tekiela A; Koralewski P; Pouget JC; Douville I; Brandely M
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):937-43. PubMed ID: 18751706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
    Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin JP; Bissery MC; Riva A; Azli N
    Ann Oncol; 2001 Jul; 12(7):909-18. PubMed ID: 11521794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer.
    Nisticò C; De Matteis A; Rossi E; Carnino F; Valenza R; Agostara B; Bria E; Farris A; Cremonesi M; D'Ottavio AM; Vaccaro A; Garufi C; Giunta S; Botti C; Perrone F; Terzoli E
    Anticancer Res; 2005; 25(2B):1343-8. PubMed ID: 15865089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.
    Esteban E; de Sande G; Puertas J; Fra J; Palacio I; Vieitez JM; Fernández JL; Muñiz I; Modollel A; Carrasco J; Sala M; Lacave AJ
    Breast Cancer Res Treat; 2000 Jul; 62(2):127-33. PubMed ID: 11016750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study.
    Rodríguez J; Calvo E; Cortes J; Santisteban M; Perez-Calvo J; Martínez-Monge R; Brugarolas A; Fernández-Hidalgo O
    Breast Cancer Res Treat; 2002 Nov; 76(1):47-56. PubMed ID: 12408375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.